Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) was the target of a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 36,300 shares, a decline of 6.7% from the July 31st total of 38,900 shares. Based on an average trading volume of 30,000 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.3% of the shares of the company are sold short.
In other news, Director Leonard Sank purchased 25,000 shares of the stock in a transaction dated Monday, September 9th. The stock was acquired at an average cost of $2.92 per share, for a total transaction of $73,000.00. Following the acquisition, the director now owns 364,999 shares of the company’s stock, valued at $1,065,797.08. The acquisition was disclosed in a filing with the SEC, which is available at this link. Insiders bought a total of 50,817 shares of company stock valued at $164,009 over the last quarter. Company insiders own 20.50% of the company’s stock.
An institutional investor recently bought a new position in Oramed Pharmaceuticals stock. Jane Street Group LLC acquired a new position in shares of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 43,212 shares of the biotechnology company’s stock, valued at approximately $155,000. Jane Street Group LLC owned about 0.25% of Oramed Pharmaceuticals at the end of the most recent reporting period. 4.83% of the stock is currently owned by institutional investors and hedge funds.
Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its quarterly earnings data on Wednesday, July 10th. The biotechnology company reported ($0.23) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.23). The firm had revenue of $0.68 million during the quarter, compared to the consensus estimate of $0.71 million. Oramed Pharmaceuticals had a negative return on equity of 56.15% and a negative net margin of 568.43%. On average, analysts forecast that Oramed Pharmaceuticals will post -0.98 earnings per share for the current year.
A number of equities research analysts have recently weighed in on the company. LADENBURG THALM/SH SH assumed coverage on Oramed Pharmaceuticals in a report on Wednesday. They issued a “buy” rating and a $7.00 price target for the company. ValuEngine upgraded Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, HC Wainwright restated a “buy” rating on shares of Oramed Pharmaceuticals in a research note on Wednesday, June 19th.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.